



#K

ATTORNEY'S DOCKET NO. I0277/7007 (HCL//KA)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Martha K. Newell, et al.
Serial No. 09/470,494
Filed: December 22, 1999
For: USE OF CD40 ENGAGEMENT TO ALTER T CELL RECEPTOR
USAGE
Examiner: not yet assigned
Art Unit: 1643

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Commissioner for Patents, Washington, D.C. 20231, on the 12th day of June, 2000.

Helen C. Lockhart

Commissioner for Patents
Washington, D.C. 20231

STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

This Information Disclosure Statement has been filed before the mailing date of a first Office Action on the merits in the above-identified case. No fee or certification is required.

The Applicants hereby make the following additional information of record in the above-identified application:

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

A copy of each of the above-identified information is enclosed unless otherwise indicated on the attached form PTO-1449 (modified).

The following is a related pending U.S. non-provisional application which does not appear on the 1449 form.

Serial No.

09/277,575

Filing Date

March 26, 1999

It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;

2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;

3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.


Respectfully submitted,

By: Helen C. Lockhart
Helen C. Lockhart, Reg No. 39,248
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210
Telephone (617) 720-3500

Docket No. I0277/7007 (HCL/KA)

Dated:

x5/22/00



FORM PTO-1449(Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.: I0277/7007	SERIAL NO.: 09/470,494
	APPLICANT: Martha K. Newell, et al.	
	FILING DATE: December 22, 1999	GROUP: 1643

U.S. PATENTS

Exam Init	Ref Des	Document No.	Date	Name	Class	Sub Class	FILING DATE If Appropriate
	A1	5,639,939	6/97	McCune, III	800	2	
	A2	5,593,972	1/97	Weiner, et al.	514	44	
	A3	5,677,165	10/97	de Boer, et al.	435	240.2	
	A4	5,677,139	10/97	Johnson, et al.	435	29	
	A5	5,674,492	10/97	Armitage, et al.	424	144.1	

FOREIGN PATENT DOCUMENTS

		Country & Doc. No. (11)	Pub. Date (43)		Class	Sub Class	Translation Yes No	
	B1	WO 98/03670	1/98	PCT				
	B2	WO 97/31025	8/97	PCT				
	B3	WO 95/09653	4/95	PCT				
	B4	WO 95/10540	4/95	PCT				

OTHER ART

(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)

	C1		Copy of the International Search Report mailed April 26, 2000
	C2		Lipsky, et al., "Analysis of CD40-CD40 Ligand Interactions in the Regulation of Human B Cell Function" <i>Ann. NY. Acad. Sci.</i> , pgs 372-383 (1997).
	C3		Schattner, et al., "CD40 Ligation Induces Apo-1/Fas Expresssion on Human B Lymphotes and Facilitates Apoptosis through the Apo-1/Fas Pathway" <i>J Exp Med.</i> 1995 Nov 1;182(5):1557-65
	C4		Fanslow, et al., "Recombinant CD40 Ligand Exerts Potent Biologic Effects on T Cells", <i>J Immunol.</i> 1994 May 1;152(9):4262-9.
	C5		Choe, et al., "Cellular and molecular factors that regulate the differentiation and apoptosis of germinal center B cells. Anti-Ig down-regulates Fas expression of CD40 ligand-stimulated germinal center B cells and inhibits Fas-mediated apoptosis", <i>J Immunol.</i> 1996 Aug 1;157(3):1006-16.
	C6		Foy, et al., "An Essential Role for gp39, the Ligand for CD40, in Thymic Selection", <i>J. Exp. Med.</i> , 182:1377-1388 (1995)
Examiner:			Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant